The National Medical Products Administration (NMPA) today approved the world's
first factor XI inhibitor for use in China. The drug, a new-mechanism,
new-target anticoagulant, is indicated for secondary prevention of
non‑cardioembolic ischemic stroke and high‑risk transient ischemic attack and
can be used alongside existing standard stroke therapies to reduce recurrent
stroke. Its mechanism suggests a potentially lower bleeding risk versus
currently approved anticoagulants.
